Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: Results of the ONTARGET trial

Journal of Hypertension

Volumn 31, Issue 2, 2013, Pages 414-421

  Mann, Johannes F E ^a   Anderson, Craig ^b   Gao, Peggy ^c   Gerstein, Hertzel C ^c   Boehm, Michael ^f   Rydén, Lars ^e   Sleight, Peter ^d   Teo, Koon K ^c   Yusuf, Salim ^c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c MCMASTER UNIVERSITY   (Canada)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e KAROLINSKA INSTITUTE   (Sweden)

^f SAARLAND UNIVERSITY   (Germany)

Author keywords

aliskiren; angiotensin receptor blockers; angiotension converting enzyme inhibitors; blood pressure; direct renin inhibitor

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; POTASSIUM; RAMIPRIL; TELMISARTAN; TRIACYLGLYCEROL;

ACUTE KIDNEY FAILURE; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOMETABOLIC RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIALYSIS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METABOLIC REGULATION; MICROALBUMINURIA; MONOTHERAPY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84872873144     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835bf7b0     Document Type: Article

References (22)

1. Ryden L, Waeber B, Ruilope LM, Mancia G, Volpe M, Holzgreve H, et al. The management of the type 2 diabetic patient with hypertension: too late and too little: suggested improvements. Blood Press 2008; 17: 250-259.
2. Group AS, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
3. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324:699-702.
4. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24:1663-1671.
5. Investigators O, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
6. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547-553.
7. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148:30-48.
8. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473-2483.
9. Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011; 123:1098-1107.
10. Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, et al. Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Ann Intern Med 2011; 154:310-318.
11. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27:1360-1369.
12. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies C. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
13. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a metaanalysis. JAMA 2011; 305:913-922.
14. Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006; 24:1201-1208.
15. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol 2012; 59:74-83.
16. Ovbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R, et al. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 2011; 306:2137-2144.
17. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134:629-636.
18. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
19. Kokubo Y, Nakamura S, Okamura T, Yoshimasa Y, Makino H, Watanabe M, et al. Relationship between blood pressure category and incidence of stroke and myocardial infarction in an urban Japanese population with and without chronic kidney disease: the Suita Study. Stroke 2009; 40:2674-2679.
20. Perkovic V, Ninomiya T, Arima H, Gallagher M, Jardine M, Cass A, et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol 2007; 18:2766-2772.
21. Ninomiya T, Perkovic V, Gallagher M, Jardine M, Cass A, Arima H, et al. Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. Kidney Int 2008; 73: 963-970.
22. Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda M, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebocontrolled study. Diabetologia 2011; 54:2978-2986.